Rituximab for the Treatment of Rheumatoid Arthritis - Coverage Criteria
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity and prior-authorization requirements for rituximab (Rituxan and biosimilars) for adults with moderately to severely active rheumatoid arthritis who have inadequate response to prior therapies; applies to Blue Cross Blue Shield of North Carolina members.
Added Riabni to the list of preferred rituximab biosimilars required to be tried before non-preferred products and explicitly included Rituxan as non-preferred.
Clarified that inadequate response to methotrexate requires maximally tolerated dosing (example: titrated to 25 mg weekly) for at least 3 months.
Changed biologic trial requirement language to require at least one biologic immunomodulator (FDA labeled or compendia supported) tried for at least 3 months, with allowances for intolerance/hypersensitivity/contraindication.
Added requirement that prescriber be a specialist or consult with a specialist and that hepatitis B screening (HBsAg and antiHBc) be performed prior to therapy.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.